*ALLIGATOR BIOSCIENCE ANNOUNCES FDA ORPHAN DRUG DESIGNATION FOR HLX22/AC101 IN GASTRIC CANCER
*UNDER TERMS OF LICENSE AGREEMENT, ALLIGATOR IS ENTITLED TO 35% OF ABCLON'S REVENUE FROM SUBLICENSE AGREEMENT WITH HENLIUS
((Reuters Investor Briefs; email: reutersinvestor.briefs@thomsonreuters.com))
Source Date/Time = 20-MAR-202514:00:02.283 GMT